Genedrive PLC Additional Listing of Shares (8702R)
19 June 2018 - 8:18PM
UK Regulatory
TIDMGDR
RNS Number : 8702R
Genedrive PLC
19 June 2018
For release: 19 June 2018
genedrive plc ("genedrive" or the "Company")
Additional Listing of Shares
Genedrive plc announces that it has issued 93,669 ordinary 1.5p
shares in the capital of the Company ("Ordinary Shares") to settle
shares owing under the Epistem Share Incentive Plan.
Application has been made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM. Admission is
expected to be effective on 25 June 2018. The Ordinary Shares shall
rank pari passu with the existing ordinary shares in the
Company.
Following admission, the Company's issued share capital will
comprise 18,783,115 Ordinary Shares and each Ordinary Share carries
one vote. There are no Ordinary Shares held in treasury and
accordingly, the total number of voting rights is 18,873,115. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Peel Hunt LLP
James Steel +44 (0)207 418 8900
Oliver Jackson
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) HCV-ID test has received CE-IVD
Certification and has been launched in Africa and Asia Pacific.
genedrive has distribution agreements with subsidiaries of Sysmex
Corporation for the distribution of the Genedrive(R) platform in
the EMEA and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd
for the distribution of the Genedrive(R) HCV ID Kit and
Genedrive(R) platform in India.
Further details can be found at: www.genedriveplc.com and
www.genedrive.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ALSUKARRWNANAAR
(END) Dow Jones Newswires
June 19, 2018 06:18 ET (10:18 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024